Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
0 hedge funds and large institutions have $0 invested in Intersect ENT, Inc in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 126 closing their positions.
100% less funds holding
Funds holding: 131 → 0 (-131)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
100% less capital invested
Capital invested by funds: $826M → $0 (-$826M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 126
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VI
Versor Investments
New York
|
-$93.1M |
| 2 |
BlackRock
New York
|
-$73.7M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$71.1M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$48.7M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
-$38.8M |
XENT Hedge Fund Activity: Q2 2022 in Review
0 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q2 2022, worth a combined $0 — down 100% from $826M a quarter earlier.
Sellers outnumbered buyers: 126 funds closed out of XENT and 0 opened new positions — a net loss of 126 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Versor Investments, exiting entirely with an estimated $93.1M sold.
- 0 institutional investors held Intersect ENT, Inc (XENT) as of Q2 2022, down from 131 in Q1 2022.
- Funds reported $0 of Intersect ENT, Inc stock for Q2 2022, down 100% quarter-over-quarter.
- 0 funds opened new Intersect ENT, Inc positions in Q2 2022 and 126 closed out, a net change of -126 holders.
- The largest Intersect ENT, Inc seller in Q2 2022 was Versor Investments, an estimated $93.1M sold.
Based on aggregated 13F filings for Q2 2022.